the drug does two things which is why Novartis chose to partner with Conatus. Emricasan causes apoptosis cell death and reduces inflammation. What that does it eliminates the bad cells in the liver clearing it out, and the reducing inflammation causes the liver to get more back to its normal state. Of course if this is proven in the phase 2b trial it will be a blockbuster drug because it is indicated for both NASH fibrosis and NASH Cirrhosis.
As for the partnership with Novartis. It is believe that Novartis Drug will further help with the reduction of Fibrosis by providing its FXR agonist together with Emericasan clearing the blood vessels in the liver and reducing inflammation.
Market Data 
Markets 
AI
